Drug news
NICE recommends peginterferon alfa plus ribavirin for Hepatitis C in children and adolescents
NICE has confirmed an earlier draft guidance which recommended peginterferon alfa in combination with ribavirin as an option for treating chronic Hepatitis C in children and young people. Pegasys (peginterferon alfa-2a), from Roche, and Viraferon Peg (peginterferon alfa-2b), from MSD, in combination with ribavirin, are the only treatments currently licensed in the UK for treating Hepatitis C in children. Final guidance is likely to be published in November 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.